{"id":"azacitidine-associated-with-valproic-acid","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Myelosuppression"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Azacitidine is a pyrimidine analog that incorporates into DNA and RNA, causing DNA hypomethylation. This results in the reactivation of silenced tumor suppressor genes, leading to cell cycle arrest and apoptosis in cancer cells. The combination with valproic acid, a histone deacetylase inhibitor, further enhances the therapeutic effect by promoting chromatin remodeling and gene expression.","oneSentence":"Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferases, leading to increased expression of tumor suppressor genes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:21.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Myelodysplastic syndromes (MDS)"}]},"trialDetails":[{"nctId":"NCT01342692","phase":"PHASE2","title":"Best Promising Drug Association With Azacitidine in Higher Risk Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06","conditions":"MDS","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Azacitidine associated with Valproic acid","genericName":"Azacitidine associated with Valproic acid","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferases, leading to increased expression of tumor suppressor genes. Used for Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}